Technological developments in the pharmaceutical and biotech industry are reflected in increased funding, higher R&D productivity and more product launches. However, the general conditions remain challenging. Incremental change won’t be enough to deliver the results that the market and patients demand, warn industry experts.
The top management of life sciences companies is very optimistic about 2024 and 2025, with over 80% of pharmaceutical, medical technology and biotechnology executives expecting profit growth for the current year and over 90% for the coming year. Around one in two companies expect profits to rise by more than 5% this year and 70% next year. These are the findings of the annual survey "Life Sciences Executives Flash Report" by consulting company Horváth.
